




PATENT
ATTORNEY DOCKET NO. 50318/011001

Certificate of Mailing: Date of Deposit: March 31, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeremy Waterman

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Olli Vuolteenaho et al. Art Unit: Not Yet Assigned

Serial No.: 10/562,081✓ Examiner: Not Yet Assigned

Filed: December 23, 2005 Customer No.: 21559

Title: Assay

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Applicants note that WO 95/28952, WO 00/19207, and WO 00/45176, which are listed on the enclosed Form PTO 1449, are in the German language. Applicants submit the English language abstracts of these documents as the concise explanations of the relevance of these documents, pursuant to 37 C.F.R. 1.98(a)(3)(i).

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: March 30, 2006

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No.	50318/011001 10/562,081
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant	Olli Vuolteenaho et al.
		Filing Date	December 23, 2005
		Group	Not Yet Assigned
(37 C.F.R. § 1.98(b))		IDS Filed	March 31, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	5,747,274	05/05/98	Jackowski			
	6,124,430	09/26/00	Mischak et al.			
	6,461,828	10/08/02	Stanton et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0 393 640	10/24/90	EP			
	EP 0 542 255	05/19/93	EP			
	EP 0 648 228	11/04/98	EP			
	EP 1 118 329	07/25/01	EP			
	WO 87/06938	11/19/87	WIPO			
	WO 91/00292	01/10/91	WIPO			
	WO 93/24531	12/09/93	WIPO			
	WO 95/28952	11/02/95	WIPO			Yes (abstract)
	WO 00/19207	04/06/00	WIPO			Yes (abstract)
	WO 00/35951	06/22/00	WIPO			
	WO 00/45176	08/03/00	WIPO			Yes (abstract)
	WO 02/74234	09/26/02	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	"Atrial Natriuretic Peptide Receptor A Precursor," Swiss-Prot ID ANPA_HUMAN Standard; PRT; 1061 AA; AC P16066; April 1, 1990.
	"Atrial Natriuretic Peptide Receptor B Precursor," Swiss-Prot ID ANPB_HUMAN Standard; PRT; 1047 AA; AC P20594, O60871, Q9UQ50; Feb 1, 1991.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50318/011001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/562,081
		Applicant Olli Vuolteenaho et al.
		Filing Date December 23, 2005
		Group Not Yet Assigned
(37 C.F.R. § 1.98(b))		IDS Filed March 31, 2006

	Buckley et al., "Plasma Concentrations and Comparisons of Brain Natriuretic Peptide and Atrial Natriuretic Peptide in Normal Subjects, Cardiac Transplant Recipients and Patients with Dialysis-Independent or Dialysis-Dependent Chronic Renal Failure," <i>Clin. Sci.</i> 83:437-444, 1992.
	Clerico et al., "Circulating Levels of Cardiac Natriuretic Peptides (ANP and BNP) Measured by Highly Sensitive and Specific Immunoradiometric Assays in Normal Subjects and in Patients with Different Degrees of Heart Failure," <i>J. Endocrinol. Invest.</i> 21:170-179, 1998.
	Daly et al., "Natriuretic Peptides in the Diagnosis of Heart Disease - First Amongst Equals?" <i>Int. J. Cardiol.</i> 84:107-113, 2002.
	De Lemos et al., "The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary Syndromes," <i>N. Engl. J. Med.</i> 345:1014-1021, 2001.
	Donald et al., "Immunohistochemical Localisation of Natriuretic Peptides in the Heart and Brain of the Gulf Toadfish <i>Opsanus beta</i> ," <i>Cell Tissue Res.</i> 269:151-158, 1992.
	Drewett et al., "The Family of Guanylyl Cyclase Receptors and Their Ligands," <i>Endocrine Reviews</i> 15:135-162, 1994.
	Dzimir et al. "Differential Regulation of Atrial and Brain Natriuretic Peptides and its Implications for the Management of Left Ventricular Volume Overload," <i>Eur. J. Clin. Invest.</i> 32:563-569, 2002.
	Hasegawa et al., "Light and Electron Microscopic Localization of Brain Natriuretic Peptide in Relation to Atrial Natriuretic Peptide in Porcine Atrium," <i>Circulation</i> 84:1203-1209, 1991.
	Hira et al., "Immunoactive Iso-ANP/BNP in Plasma, Tissues and Atrial Granules of the Rat," <i>Regulatory Peptides</i> 44: 1-9, 1993.
	Kannel et al., "Changing Epidemiological Features of Cardiac Failure," <i>Br. Heart J.</i> 72 (Supplement):3-9, 1994.
	Kohse et al., "Quantitative Determination of Natriuretic Peptides in Human Biological Samples with a Bioassay Using Cultured Cells," <i>Eur. J. Clin. Chem. Clin. Biochem.</i> 30: 837-845, 1992.
	Mair et al., "The Impact of Cardiac Natriuretic Peptide Determination on the Diagnosis and Management of Heart Failure," <i>Clin. Chem. Lab Med.</i> 39:571-588, 2001.
	Masson et al., "Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failure," <i>Clin. Chem. Lab Med.</i> 40:761-763, 2002.
	McDonagh et al., "Symptomatic and Asymptomatic Left-Ventricular Systolic Dysfunction in an Urban Population," <i>Lancet</i> 350:829-833, 1997.
	Omland et al., "N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes," <i>Circulation</i> 106:2913-2918, 2002.
	Remes et al., "Validity of Clinical Diagnosis of Heart Failure in Primary Health Care," <i>Eur. Heart J.</i> 12:315-321, 1991.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50318/011001
		Serial No.	10/562,081
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant	Olli Vuolteenaho et al.
		Filing Date	December 23, 2005
		Group	Not Yet Assigned
(37 C.F.R. § 1.98(b))		IDS Filed	March 31, 2006

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	